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Abstract
Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy, 
which often presents at an advanced stage. A proportion of SDC are characterized by 
HER2 amplification and/or overexpression of androgen receptor (AR), which could 
be targeted in a subset of patients, but the presence of AR splice variant‐7 (AR‐V7) 
in some SDC cases could result in resistance to anti‐androgen therapy. We evaluated 
a cohort of 28 cases of SDC for potentially targetable biomarkers and pathways using 
immunohistochemistry (IHC) and next‐generation sequencing (DNA and RNA) as-
says. Pathogenic genetic aberrations were found in all but 1 case and affected TP53 
(n = 19), HRAS (n = 7), PIK3CA, ERBB2 (HER2), and NF1 (n = 5 each); KMT2C 
(MLL3) and PTEN (n = 3 each); BRAF (p.V600E), KDM5C and NOTCH1 (n = 2 
each). Androgen receptor was expressed in all cases and 13 of 27 harbored the AR‐
V7 splice variant (including a case without any other detectable genetic alteration). 
HER2 IHC was expressed in 11 of 28 cases. The majority of SDC cases had no 
biomarkers predictive of immunotherapy response: 5 cases exhibited low (1%‐8%) 
programmed death ligand 1 (PD‐L1) expression in tumor cells, 2 cases exhibited 
elevated TMB, and no samples exhibited microsatellite instability. Notably, the pre‐
treatment biopsies from 2 patients with metastatic disease, who demonstrated clinical 
responses to anti‐androgen therapy, showed AR expression and no AR splice vari-
ants. We conclude that comprehensive molecular profiling of SDCs can guide the 
selection of patients for targeted therapies involving AR, HER2, PD‐L1, mitogen‐ac-
tivated protein kinase, and PIK3CA pathways.
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1 |  INTRODUCTION
Salivary duct carcinoma (SDC) is a rare, high‐grade salivary 
gland malignancy characterized by an apocrine phenotype and 
morphologic similarity to ductal carcinoma of the breast.1 Men 
over the age of 50 are most frequently affected, and the parotid 
gland is the most common site. SDC tends to present with 
an enlarging mass sometimes accompanied by facial nerve 
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paralysis.2 With the exception of cases occurring as intracap-
sular SDC ex pleomorphic adenoma (PA), this tumor is highly 
aggressive. Patients often present with advanced stage disease 
including frequent nodal metastases, and overall survival is 
poor, with approximately 65% of patients dying from pro-
gressive disease within 48 months.2,3 Standard management 
for SDC consists of surgical resection followed by radiation 
therapy; however, local recurrence and metastatic rates remain 
high, and treatment options for recurrent and metastatic SDC 
are limited.3 Therefore, there is an unmet need for targeted 
therapies to help better manage this aggressive malignancy.
Several characteristic findings in SDC have been ex-
ploited in the development of targeted therapy including 
the overexpression of HER2/neu (ERBB2) found in 37% of 
SDC ERBB2 gene amplification is found in 72% of over-
expressing cases.2 Clinical responses to HER2‐targeted 
agents, alone or in combination with chemotherapy, have 
been reported in individual patients with HER2 + SDC.4-7 
Additionally, androgen receptor (AR) expression which is a 
defining feature of SDC, is found in up to 98% of cases.1,8 
Some argue that AR‐negative SDC is virtually non‐existent, 
as many such cases are either AR‐positive after repeat im-
munohistochemistry (IHC) testing, or are subsequently re-
classified as a different entity with morphologic similarities 
to SDC.1 As a result, androgen deprivation therapy (ADT) 
has emerged as another potential targeted therapeutic strat-
egy for SDC patients, potentially even in the adjuvant 
setting, and has shown promising results in several small 
studies.9-13
Despite some headway in targeted therapy for SDC, nei-
ther anti‐HER2 nor anti‐androgen therapies have been stan-
dardized or clinically validated. In addition, mechanisms 
of resistance to HER2‐based treatments and ADT may hin-
der its clinical benefit in some patients.14,15 For instance, 
alterations in phosphoinositide 3‐kinase (PI3K) signaling, 
either by PIK3CA mutation or PTEN loss, may be involved 
in resistance to HER2‐targeted therapy.15 Additionally, the 
discovery of constitutively active AR splice variants, no-
tably AR splice variant‐7 (AR‐V7), which are implicated 
in resistance to ADT in prostate cancer, has led to the dis-
covery of these variants in SDC specimens as well.14,16-
18 A small study conducted by Cappelletti et al16 suggests 
that the presence of AR‐V7 in SDC cells may likewise 
affect response to ADT, but this requires more extensive 
investigation.
The treatment of numerous solid and hematologic ma-
lignancies (eg non‐small cell lung carcinoma, bladder car-
cinoma, melanoma, classical Hodgkin lymphoma) has been 
markedly improved due to therapy with immune check point 
inhibitors against programmed death 1 and its ligand PD‐L1 
(immuno‐oncology [I‐O] treatment). Predictors of a response 
to these inhibitors include the expression of PD‐L1 in can-
cer or tumor‐associated immune cells (IC), tumor mutational 
burden (TMB), microsatellite instability (MSI) status, and 
the presence of tumor infiltrating lymphocytes.19-21 While 
immunotherapy has not yet been clinically validated for the 
treatment of salivary gland malignancies including SDC, sev-
eral trials are underway. A study of Cohen et al22 revealed a 
modest therapeutic benefit (12% response rate) of pembroli-
zumab in the patients with PD‐L1 positive (≥1% positive 
cancer or IC) SDC, and it is thought that a combination treat-
ment with chemotherapy may improve the clinical response 
rates (NCT03360890).
In this study, we report the findings from comprehensive 
molecular profiling focusing on identification of potential 
novel molecular targets and I‐O biomarkers in a cohort of 
SDC.
2 |  MATERIALS AND METHODS
2.1 | Patients and samples selection
Twelve cases of primary SDC from the Department of 
Pathology at Thomas Jefferson University Hospital and 16 
cases of SDC (6 primary cases and 10 recurrent/metastatic 
SDC cases, including one matched primary and metastatic 
tumor from the same patient) from Caris Life Sciences met 
the following inclusion criteria: Confirmed diagnosis of SDC 
and availability of sufficient formalin‐fixed paraffin‐em-
bedded tissue from the primary and/or recurrent/metastatic 
tumor for molecular assays. All cases were re‐reviewed by a 
board‐certified pathologist to confirm the diagnosis and se-
lect appropriate slides for molecular profiling. A case was 
considered as SDC ex PA if histologic evidence of a PA was 
present in the same specimen, or if there was a clinical history 
of PA occurring previously in the same site. The Institutional 
Review Board of the Thomas Jefferson University Hospital 
approved the study (IRB #18D.142).
2.2 | Immunohistochemistry
Quantification of AR staining (SP107 clone; Ventana) was 
performed with positivity defined as strong nuclear staining 
in ≥10% of tumor cells. Detection of the splice variant AR‐
V7 was assessed at protein level by IHC (EPR15656; Abcam) 
(16 cases from Caris) and at mRNA level by anchored mul-
tiplex PCR for targeted RNA sequencing (ArcherDX) (12 
cases from Thomas Jefferson University Hospital).
Positive HER2 IHC was defined as 3+ (strong membranous 
staining) in ≥10% of tumor cells. IHC for CD274 (PD‐L1) 
was performed using either 28‐8 (Agilent) or SP142 (Ventana) 
clones, and PD‐L1 positivity was defined as membranous ex-
pression in ≥1% cancer cells (TC).23 Additionally, PD‐L1 ex-
pression on the IC was recorded. All IHC assays were run with 
both positive and negative controls using fully automated stain-
ing platforms (Ventana‐Roche and DAKO‐Agilent). The assays 
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were conducted in a CLIA/CAP/ISO15189 certified clinical 
laboratory (Caris Life Sciences).23
2.3 | Next‐generation sequencing
Next‐generation sequencing (NGS) was performed using 
two commercially available platforms: the Caris Life 
Sciences (n  =  22) and Foundation Medicine (n  =  6). The 
Caris panel utilizes SureSelect XT biotinylated RNA probes 
from Agilent, to capture DNA fragments from the exons of 
592 genes. Sequencing is performed using NextSeq instru-
ments from Illumina. The complete list of the tested genes 
is available here: http://www.caris molec ulari ntell igence.
com/solid_tumors_inter national.24 The Foundation Medicine 
NGS platform was reported previously.25 For variant classi-
fication, variants of genes that were pre‐determined for their 
cancer related and clinical significance were interpreted by 
board‐certified clinical molecular geneticists at Caris and 
categorized as pathogenic, presumed pathogenic, variant of 
unknown significance, presumed benign, or benign accord-
ing to American College of Medical Genetics and Genomics 
standards.
The TMB was assessed by counting the number of non-
synonymous missense mutations excluding common germ-
line variants. TMB was considered high if ≥10 mutations/
megabase were detected. This threshold was calculated based 
on Caris Life Sciences' cohort of 148 salivary gland carcino-
mas using the 80th percentile cutoff value as recently sug-
gested by Samstein et al.26
Microsatellite instability status was explored in 18 cases by 
analyzing the microsatellite loci of the genes on the Caris panel, 
as reported previously.23 Gene copy number variations were as-
sessed in 22 cases by comparing the depth of NGS sequence 
reads on the Caris panel to reads from a diploid control. Genes 
harboring with ≥6 copies were considered amplified.23,27
ArcherDx FusionPlex Assay (ArcherDX) was used to 
search for gene fusions. Fifty‐three gene targets were ana-
lyzed in 12 SDCs (the panel is available here: https ://www.
caris molec ulari ntell igence.com/tumor-profi ling-menu/mi-
profi le-usa-exclu ding-new-york).28
3 |  RESULTS
3.1 | Clinical characteristics of the cohort
Table 1 summarizes the cohort's characteristics; clinical 
follow‐up information was available for 12 patients (from 
Thomas Jefferson University Hospital). In accordance with 
known trends, the majority of the patients were elderly men 
with tumor in the parotid gland, and 12/12 patients with avail-
able clinical follow‐up presented with nodal (specifically 
stage pN2b) metastatic disease. In the cohort from Caris Life 
Sciences, 8 patients were with metastatic lesions (involving 
liver, lung, brain, skin, bone, and lymph nodes), 2 with local 
recurrences involving the skin, and 6 with primary tumors; 
clinical follow‐up was not available for this group.
T A B L E  1  Summary of clinicopathologic features including 
patient demographics, tumor characteristics, treatment, and follow‐up
Clinicopathologic feature N (%)
Age, mean (range) (y) 66.25 (41‐91)
Sex
Male 24/27 (89%)
Female 3/27 (11%)
Primary tumor site
Parotid 24/27 (89%)
Submandibular 2/27 (7%)
Lip 1/27 (4%)
Source of neoplastic tissue
Primary tumor, de novo SDC 13/28 (46%)
Primary tumor, SDC ex pleomorphic 
adenoma
5/28 (18%)
Recurrent/metastatic SDC 10/28 (36%)
pT stage
1 3/12 (25%)
2 0/12 (0%)
3 2/12 (17%)
4 7/12 (58%)
pN stage
0 0/12 (0%)
1 0/12 (0%)
2 12/12 (100%) (all 
stage pN2b)
Treatment
Chemoradiotherapy (CRT) 4/12 (33%)
Radiotherapy 7/12 (58%)
Anti‐androgen therapy 2/12 (17%) (both 
combined with CRT)
No therapy (surveillance) 1/12 (8%)
Follow‐up, mean (range) (mo) 18.4 (4‐45)
Clinical outcome
NED 6/12 (50%)
AWD 2/12 (17%) (1 
DM + 1 LR)
DOD 1/12 (8%)
DOC 1/12 (8%)
LTF 2/12 (17%)
Abbreviations: AWD, alive with disease; DM, distant metastasis; DOC, died of 
another cause; DOD, died of disease; LR, locoregional recurrence; LTF, lost to 
follow‐up; NED, no evidence of disease; SDC, salivary duct carcinoma.
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3.2 | Treatment and clinical follow‐up
Following surgical resection, 7 of 12 received adjuvant ra-
diation therapy, 4 of 12 received chemoradiotherapy, and 1 
patient received no additional therapy.
Two patients (1 male, 1 female) with distant metastatic 
disease were treated with anti‐androgen therapy (one re-
ceived bicalutamide and the other received enzalutamide), 
both in conjunction with chemoradiotherapy. One pa-
tient had lung metastases at the time of diagnosis, and 
she was alive with stable pulmonary metastatic disease at 
42 months after initial diagnosis. The other patient demon-
strated a total reduction in metastatic tumor burden of 28% 
after two scans, and then showed stable disease at the time 
of his third scan but passed away soon afterward. Neither of 
these patients had AR‐V7 detected in their tumor samples.
3.3 | Molecular characteristics of SDCS
Results of molecular profiling assays are summarized in 
Table 2. HER2 was overexpressed in 39% (11/28) of the 
cases. All 28 cases expressed strong nuclear staining for AR 
by IHC (100%) (Figure 1D), and 13/27 (48%) harbored splice 
variant AR‐V7 detected by either variant‐specific antibody 
(showing nuclear localization) (Figure 2) or mRNA (Table 
2). AR‐V7 positivity by IHC (n = 16) ranged from 10%‐95% 
(mean 53%) of tumor cells. A single case without any de-
tected pathogenic mutation in our cohort had AR‐V7 present 
in the tumor.
A case with matched primary and metastatic SDC har-
bored identical TP53 and ERBB2 mutations in both samples. 
A case of SDC ex PA harbored a TP53 mutation in the car-
cinoma component, while the PA component was devoid of 
any mutation. Additionally, in this case (Figure 1A‐C), HER2 
was positive in the carcinoma but negative in the adenoma 
component (Figure 1E). Both PA and SDC were devoid of 
AR‐V7.
3.4 | Genomic profile of SDCS
Pathogenic genetic alterations were detected in 27 of 28 
cases, many of which harbored more than one alteration. 
The most frequently encountered were TP53 (n  =  19), 
HRAS (n  =  7), PIK3CA (n  =  5), NF1 (n  =  5), ERBB2 
T A B L E  2  Summary of molecular genetic features of salivary duct carcinomas
Molecular genetic features
Androgen receptor (AR) 100% positive (28/28) via IHC 13/27 (48%) had AR‐V7 (9 primary, 
4 recurrent/metastatic)
HER‐2/neu receptor 11/28 (39%) positive via IHC
Mutational profilea n = 19 (68%): TP53
n = 7 (25%): HRAS
n = 5 (18%): PIK3CA, NF1
n = 3 (11%): MLL3, PTEN
n = 2 (7%): BRAF, ERBB2, KDM5C, NOTCH1
n = 1 (4%): FGFR1, CDKN1B, CREBBP, MLL2, CHEK2, RB1, BAP1, AKT1, PBRM1, SF3B1, ARID1A, 
SMARCE1, KMT2C, FBXW7, TSC2, PIK3R1, ATRX, C176Y
Gene amplifications NOTCH1 (n = 2, both primary)
ERBB2 (n = 4, 3 primary cases and 1 metastatic case)
SDC4 (n = 1, primary case)
EGFR (n = 1, metastatic case)
MDM2, LGR5, KDM5A, ERC1, CDC73 (all in one metastatic case)
Archer fusion panel (n = 12) WASF2:FGR (n = 1)
TBL1XR1:PIK3CA (n = 1)
FGFR2:PAWR (n = 1)
Predictors to immune checkpoint inhibitors
PD‐L1 expressionb 23/28 (82%) negative
5 cases (18%) with low PD‐L1 positivity (1%‐8% positive cancer 
cells)b
One case with PD‐L1 amplification
Tumor mutational burden 
(TMB)
Low (range 3‐6) in 20/22 (91%)
High (14 and 16 mutations per Mb) in 2/22 (9%)
Microsatellite instability status 100% (18/18) microsatellite stable
Abbreviations: AR‐V7, androgen receptor splice variant‐7; IHC, immunohistochemistry; PD‐L1, programmed death ligand 1.
aFull sequencing was performed using two different platforms: the Caris Life Sciences (n = 22) and Foundation Medicine (n = 6). 
bPD‐L1 expression was assessed by 28‐8 (Agilent) and SP142 (Ventana) clones. 
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(n = 5) (3 cases with amplification alone, 1 [matched pri-
mary and metastatic case] with point mutation p.L755S 
alone, and 1 case with amplification and two point muta-
tions: p.R678Q, p.V842I), KMT2C (n = 3), PTEN (n = 3), 
BRAF (p.V600E), KDM5C and NOTCH1 (n  =  2 each). 
All other mutations were rare and affected single SDCs 
(Table 2). Co‐mutations of HRAS (p.Q61R) and PIK3CA 
(p. E542A, p.H1047R) genes were seen in 5 of 7 cases with 
HRAS mutations, all of which were de novo SDC with con-
comitant HER2 overexpression.
Gene fusion results, available for 12 cases from Caris, 
were rare and included WASF2:FGR, TBL1XR1:PIK3CA, 
and FGFR2:PAWR fusions in single cases (Table 2).
3.5 | I‐O biomarkers in SDCS
Five cases had detectable (≥1% of tumor cells) PD‐L1 ex-
pression, and only 2 cases exhibited more than 5% tumor cell 
PD‐L1 expression. One case showed PD‐L1/JAK2 gene co‐
amplification by NGS but was negative for PD‐L1 expression 
by IHC. Immune cells expression of PD‐L1 was detected in 5 
cases (3 cases without detectable TC PD‐L1 expression) but 
was not scored due to the lack of uniform criteria.
All tested samples (n  =  18) were microsatellite stable 
(MSS). Twenty of 22 tested cases had a low TMB (range 3‐6 
mutations/Mb), while 2 cases (one primary and one recurrent 
SDC) had TMB > 10 per Mb (14 and 16 mutations per Mb). 
Both of these cases were PD‐L1 negative.
4 |  DISCUSSION
In this study, we explored the molecular genetic characteris-
tics of a well‐defined cohort of patients with SDC. Our study 
revealed common mutations affecting the mitogen‐activated 
protein kinase (MAPK) and PIK3CA/AKT pathways along 
F I G U R E  1  Case of salivary duct carcinoma ex pleomorphic adenoma (A‐C, hematoxylin and eosin, 10×) showing expression of androgen 
receptor (D, 10×), HER2 (E, 10×), and programmed death ligand 1 (F, 10×) restricted to the malignant component only
F I G U R E  2  Case of metastatic 
salivary duct carcinoma in the liver (A, 
hematoxylin and eosin, 20×) showing 
diffuse nuclear expression of androgen 
receptor splice variant‐7 (B, 20×)
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with consistent AR and frequent HER2 expression. The mo-
lecular genetic landscape of our SDC specimens is compara-
ble to findings in other studies on SDC and closely resembles 
that of apocrine breast cancer.2,29,30
Half of the tumors studied harbored alterations in MAPK 
pathway (HRAS/BRAF/NF1) genes, which is in line with a re-
cent study of Dalin et al30 HRAS gene mutations were partic-
ularly common (25%) indicating their significant oncogenic 
potential in SDCs. These mutations were not mutually exclu-
sive with PIK3CA mutations as co‐mutations were present in 
5 of 7 HRAS‐mutated cases. This observation was recently re-
ported in SDC by Dalin et al30 and previously in other cancer 
types.31 In contrast to Dalin et al,30 who found co‐occurring 
PIK3CA mutations in all of their cases with HRAS p.G13R 
(n = 3) but none of their cases with HRAS p.Q61R (n = 4), all 
5 of our PIK3CA/HRAS co‐mutated cases harbored the HRAS 
p.Q61R mutation. Therefore, both HRAS p.Q61R and p.G13R 
seem to interact with PIK3CA in promoting oncogenesis in 
SDC. Furthermore, combined HRAS/PIK3CA mutations 
were found in de novo SDC cases and none of our SDC ex 
PA cases, which is a similar finding to that of Chiosea et al.32 
The finding of frequent PIK3CA/HRAS co‐mutations in SDC 
may be clinically relevant as a potential cause of anti‐HER2 
resistance given that all 4 of our cases with PIK3CA/HRAS 
co‐mutations were also HER2‐positive. However, none of the 
12 patients from our cohort has been treated with anti‐HER2 
agents although previous data indicate a significant clinical 
benefit of trastuzumab‐based therapy among patients with 
HER2‐positive SDC.6,30,33,34 More recent studies suggest that 
dual HER2 inhibition with trastuzumab plus pertuzumab, 
which is a HER2 dimerization inhibitor antibody, or trastu-
zumab plus chemotherapy, may lead to even better clinical 
outcomes when compared to trastuzumab alone.35,36
While mutations in PIK3CA, HRAS, and BRAF seem to 
be more common in de novo SDC, SDC ex PA have been re-
ported to more frequently overexpress HER family members 
such as HER2, HER3 (ERBB3), and EGFR.37 In our study, 
4 of 5 SDC ex PA, 5 of 13 de novo SDC, and 2 of 10 recur-
rent/metastatic SDC were positive by HER2 IHC. In a large 
series of 151 SDCs, PIK3CA/HRAS/BRAF mutations and 
HER2 positivity were reported to be mutually exclusive.37 
In contrast, in our 7 cases with PIK3CA/HRAS/BRAF muta-
tions, 4 cases (all with PIK3CA/HRAS co‐mutations) showed 
HER2 expression by IHC. However, the 2 cases with HRAS 
mutation alone, along with 1 case with BRAF p.V600E, were 
negative for HER2 IHC. Additionally, the 2 cases with HER2 
amplification did not show PIK3CA/HRAS/BRAF mutations, 
suggesting that perhaps HER2 amplification but not HER2 
overexpression by IHC alone may be mutually exclusive with 
these mutations.
The presence of PIK3CA mutations in a subset of SDC rep-
resents a viable therapeutic target. A large series of patients 
with various tumor histologies showed that the presence of the 
PIK3CA p.H1047R mutation specifically was an independent 
predictor for tumor response to PI3K pathway inhibitors.38 All 
4 of our patients with PIK3CA mutations had this particular 
mutation, and one had a concurrent PIK3CA p.E542A mu-
tation. Besides PIK3CA mutations, loss of PTEN activates 
the PI3K pathway and thus may represent another potential 
target. Several studies have reported frequent loss of PTEN 
expression, detected via IHC or FISH analysis, in up to 51% of 
SDC.15,37 In head and neck squamous cell carcinoma, tumor 
cells with PTEN loss were shown to be commonly resistant 
to pan‐PI3K inhibitors; however, in vitro studies have shown 
promising results for targeted PI3K therapy in SDC cells.15 
Finally, the discovery of a TBL1XR1‐PIK3CA fusion, which 
has been reported to result in overexpression of the complete 
PIK3CA protein, in one of our cases further supports the im-
portant role of PIK3CA in the oncogenesis of SDC.39
The BRAF p.V600E mutation was detected in two of 
our cases, similarly to the previously reported studies.2,32,37 
Although the overall percentage of SDCs with mutated BRAF 
may be low, there is a potential for targeted therapy for these 
patients, as BRAF inhibitors are used successfully in mela-
noma and other BRAF‐mutated tumors. A phase 2 study of 
vemurafenib in a variety of BRAF p.V600 mutation‐positive 
non‐melanoma cancers showed partial response in 1 patient 
with SDC.40 Additionally, a recent report describes a patient 
who presented with widely metastatic disease and achieved 
an excellent response to combination chemotherapy with 
dabrafenib (BRAF inhibitor) and trametinib (MEK inhibi-
tor).41 Clearly, routine testing for BRAF mutations in SDC 
seems warranted to select patients for targeted therapy.
The presence of AR‐V7, a biomarker predictive of re-
sistance to anti‐androgen therapy in prostate carcinoma, in 
13/27 (48%) of cases of SDC indicates a potential role for 
refining patient selection for hormonal therapies. The AR‐V7 
splice variant encodes a truncated AR protein that possesses 
only the transactivating N‐terminal domain without the C‐
terminal ligand‐binding domain (which normally serves as 
the binding site for anti‐androgen agents), resulting in consti-
tutive activation of AR.3,8 With the use of RT‐PCR or RNA 
sequencing, AR‐V7 mRNA has been reported in up to 50% 
of SDC tumors.17 Other AR isoforms such as AR‐V3 and 
AR‐45 are found less frequently and with unknown clini-
cal significance.8 The presence of AR‐V7 in prostate can-
cer tumor cells has been associated with resistance to ADT, 
though there are limited studies thus far regarding its effect 
in SDC response to anti‐androgen therapy.17,42 Cappelletti 
et al16 report a single patient with SDC treated with ADT 
who developed resistance and was found to have AR‐V7 in 
circulating tumor cells. In our study, the 2 patients treated 
with ADT did not have AR‐V7 in their initial tumor samples, 
and they showed clinical response in the form of stabilization 
of the disease. Interestingly, the tumors with AR‐V7 in our 
study harbored this protein prior to initiation of any systemic 
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therapies, as the tissue tested came from tumor samples from 
the initial surgical resection. Therefore, it seems that prior 
exposure to ADT is not necessary for the development of 
AR‐V7 in SDC. Kang et al17 report a similar finding, in that 
SDC specimens from 2 patients with no prior exposure to 
ADT demonstrated high signal for AR‐V7 with RNA in situ 
hybridization (RISH). Additionally, they found that only 1 
patient of 3 treated with ADT had clinical benefit, and this 
patient was AR‐V7 negative by RISH.17
We also explored the previously established predictive 
biomarkers to immune checkpoint inhibitors including PD‐
L1, TMB and MSI status. Five of our cases exhibited low 
level (1%‐8%) PD‐L1 expression in tumor cells. A recent 
study by Sato et al,43 which utilized the PD‐L1 clone E1L3N 
(Cell Signaling Technology), revealed higher rates of PD‐L1 
expression in SDC tumor cells, with 4 of 18 cases show-
ing high expression (defined as greater than 10%) and 5 of 
18 cases showing low expression (1%‐9%); moreover high 
PD‐L1 expression strongly correlated with shorter overall 
survival. In our study, two different anti‐PD‐L1 assays (lab-
oratory developed SP142 assay and 28‐8 complementary 
diagnostic assay used for head and neck squamous cell carci-
noma) were used in 2 different groups of cases, respectively. 
We found 1/12 TC positive using 28‐8 and 4/16 TC posi-
tive using SP142 clones. Importantly, all tested cases were 
MSI stable (tissue site agnostic assay for the use of pem-
brolizumab), while the vast majority (20/22) exhibited low 
TMB. Based on the obtained data for predictive biomark-
ers, SDC patients are less likely to benefit from the immune 
checkpoint inhibitors. In a clinical trial of 26 patients with 
PD‐L1‐positive advanced salivary gland cancer of various 
histologies, the objective response rate for pembrolizumab 
monotherapy was only 12%.22 However, additional trials 
(NCT03360890) are underway with the hope of achieving 
improved clinical response rates using combination pem-
brolizumab plus chemotherapy.
In summary, SDC is a genetically diverse neoplasm associ-
ated with several potentially targetable molecular pathways, in-
dicting the need for individual patient's tumor assessment. Some 
of the detected molecular alterations (eg AR‐V7, PIK3CA, 
HRAS) may undermine the therapeutic benefits of standardized 
treatments (anti‐AR and anti‐HER2). The predictive biomark-
ers to immune checkpoint inhibitors indicate a small potential 
for therapeutic benefit of these agents in some patients.
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